Abstract 418P
Background
Mutational landscape studies, facilitated by next-generation sequencing technologies, can improve our understanding of cancer pathogenesis and help identify potentially targetable alterations. In this study, we aimed to provide an overall description of the mutational landscape in non-small cell lung cancer (NSCLC) using publicly available sequencing data.
Methods
We used the American Association for Cancer Research’s Project Genomics Evidence Neoplasia Information Exchange (GENIE) [GENIE Cohort v11.0-public study] to obtain sequencing data for patients diagnosed with NSCLC. Mutational profiles were described according to race (White, Black, or Asian) and histopathology (adenocarcinoma or squamous cell carcinoma). We used the OncoKB to assess the actionability of frequently mutated genes in the studied cohort.
Results
We included 16,498 samples (13,927 White, 1,304 Black, and 1,267 Asian; 12,790 adenocarcinoma, and 1,546 squamous cell carcinoma). TP53 was the most frequently mutated gene, with half of the analyzed samples (49.6%) containing at least one TP53-related molecular alteration. TP53 mutation rate was higher in cases with squamous cell carcinoma compared to cases with adenocarcinoma (76.7% vs. 45.6%; p<0.001). In race-dependent subgroup analysis, mutations in EGFR gene occurred in about 53.3% of Asian cases to rank as the most frequently mutated gene in this subgroup (Table). Most of the frequently mutated genes in NSCLC (especially in the squamous cell carcinoma subgroup) are still not actionable (Table). Table: 418P
Commonly mutated genes in NSCLC
Adenocarcinoma | Squamous Cell | White | Black | Asian |
TP53 (45.6%) | TP53 (76.6%) | TP53 (49.2%) | TP53 (55.7%) | EGFR (53.3%) * |
KRAS (32.2%) * | KMT2D (22.1%) | KRAS (30%) * | PCM1 (25%) | TP53 (48.2%) |
EGFR (25.8%) * | PRKDC (11.5%) | EGFR (18.8%) * | KRAS (24.8%) * | KRAS (10.6%) * |
KEAP1 (13.5%) | PCM1 (11.3%) | KEAP1 (14.6%) | EGFR (20.6%) * | RBM10 (9.5%) |
SKT11 (13.1%) * | KEAP1 (11%) | LRP1B (13%) | KEAP1 (11.8%) | KMT2D (6.9%) |
* gene with actionable mutation(s)
Conclusions
Despite progress in the targetability of NSCLC, many of the most frequently mutated genes are still not actionable. Genomic profiling has the potential to identify potential targets of interest, which could guide individualized treatment plans to address the current high burden of NSCLC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
462P - Limited duration of treatment with checkpoint inhibitors in complete responders, yet prolonged survival: A real-world study from India
Presenter: Nitin Murthy
Session: Poster viewing 06
463P - Cost effectiveness of palbociclib and ribociclib in metastatic breast cancer in India using ICER and QALY
Presenter: Krishnamani Kalpathi
Session: Poster viewing 06
464TiP - Phase III study of adjuvant encorafenib plus binimetinib vs placebo in fully resected stage IIB/C BRAFV600-mutated melanoma: COLUMBUS-AD study design
Presenter: Alexander van Akkooi
Session: Poster viewing 06
465TiP - Evaluation of quality of life and functional outcomes following limb salvage surgery in extremities sarcomas
Presenter: naveen kushwaha
Session: Poster viewing 06
YO2 - A case of locally advanced breast cancer with biomarker conversion successfully treated with neoadjuvant chemotherapy-immunotherapy combination
Presenter: Long Nguyen
Session: Poster viewing 06
YO3 - Metastatic Breast cancer to esophagus: A case report and review of literature
Presenter: Bhuvana J
Session: Poster viewing 06
YO4 - Succinate Dehydrogenase deficient GISTs is a diagnostic and therapeutic dilemma? : A case report.
Presenter: Nurazzahra Kamarudin
Session: Poster viewing 06
YO5 - Complete Radiologic and Pathologic Response in a Metastatic Gallbladder Adenocarcinoma Patient treated with Checkpoint Inhibitor/Chemotherapy Combination: A Case Report
Presenter: Tisha Gay Tancongco
Session: Poster viewing 06
YO7 - Orbital Metastasis in Prostrate Cancer: A Case Report
Presenter: Shabnam Rehman
Session: Poster viewing 06
YO10 - BRCA2 Mutated Recurrent Adult Granulosa Cell Tumor Treated with PARP Inhibitor
Presenter: Debapriya Mondal
Session: Poster viewing 06